Related Experiment Video
Updated: Apr 12, 2026
Procedure for Lung Engineering
Published on: March 8, 2011
Cell-based therapy in lung regenerative medicine
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 USA.
Abstract:
Chronic lung diseases are becoming a leading cause of death worldwide. There are few effective treatments for those patients and less choices to prevent the exacerbation or even reverse the progress of the diseases. Over the past decade, cell-based therapies using stem cells to regenerate lung tissue have experienced a rapid growth in a variety of animal models for distinct lung diseases. This novel approach offers great promise for the treatment of several devastating and incurable lung diseases, including emphysema, idiopathic pulmonary fibrosis, pulmonary hypertension, and the acute respiratory distress syndrome. In this review, we provide a concise summary of the current knowledge on the attributes of endogenous lung epithelial stem/progenitor cells (EpiSPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) in both animal models and translational studies. We also describe the promise and challenges of tissue bioengineering in lung regenerative medicine. The therapeutic potential of MSCs is further discussed in IPF and chronic obstructive pulmonary diseases (COPD).
Insights
Stem cell therapies show promise for regenerating lung tissue and treating chronic lung diseases like COPD and pulmonary fibrosis. Research explores various stem cell types and tissue bioengineering for lung repair.
Area of Science:
- Regenerative Medicine
- Pulmonology
- Cell Biology
Background:
- Chronic lung diseases are a major global health concern with limited effective treatments.
- Cell-based therapies using stem cells are emerging as a promising approach for lung tissue regeneration.
- Existing treatments offer few options for preventing exacerbations or reversing disease progression.
Purpose of the Study:
- To review current knowledge on endogenous lung epithelial stem/progenitor cells (EpiSPCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells (EPCs) for lung regeneration.
- To discuss the potential and challenges of tissue bioengineering in lung regenerative medicine.
- To explore the therapeutic applications of MSCs in idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary diseases (COPD).
Main Methods:
- Review of current scientific literature on stem cell therapies for lung diseases.
- Analysis of preclinical animal models and translational studies.
- Evaluation of tissue bioengineering strategies for lung repair.
Main Results:
- Endogenous EpiSPCs, MSCs, and EPCs demonstrate potential in preclinical models for various lung diseases.
- Tissue bioengineering offers novel avenues for lung tissue regeneration.
- MSCs show therapeutic promise for IPF and COPD.
Conclusions:
- Cell-based therapies represent a significant advancement in treating debilitating lung diseases.
- Further research and development in stem cell applications and tissue bioengineering are crucial for clinical translation.
- Regenerative medicine holds great promise for improving outcomes in patients with chronic lung conditions.
More Related Videos
09:45Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease
Published on: April 12, 2021
16:45Nonhuman Primate Lung Decellularization and Recellularization Using a Specialized Large-organ Bioreactor
Published on: December 15, 2013
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:17Stem Cell Culture
01:22iPS Cell Differentiation